Warfarin

Generic Name
Warfarin
Brand Names
Coumadin, Jantoven
Drug Type
Small Molecule
Chemical Formula
C19H16O4
CAS Number
81-81-2
Unique Ingredient Identifier
5Q7ZVV76EI
Background

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication

Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions
Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
Associated Therapies
-

A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants

First Posted Date
2011-09-13
Last Posted Date
2014-10-07
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
28
Registration Number
NCT01432938
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States

A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers

Phase 1
Completed
Conditions
Interventions
First Posted Date
2011-07-22
Last Posted Date
2017-01-24
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
46
Registration Number
NCT01400646

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

First Posted Date
2011-07-12
Last Posted Date
2023-11-29
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
34
Registration Number
NCT01391962
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin

First Posted Date
2011-07-06
Last Posted Date
2020-07-01
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
13
Registration Number
NCT01388335
Locations
🇫🇷

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France

A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

First Posted Date
2011-04-25
Last Posted Date
2017-11-13
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
48
Registration Number
NCT01340846
Locations
🇬🇧

GSK Investigational Site, London, United Kingdom

Effects of Administration of Fostamatinib on Blood Concentrations of Warfarin in Healthy Subjects

First Posted Date
2011-03-09
Last Posted Date
2013-01-31
Lead Sponsor
AstraZeneca
Target Recruit Count
15
Registration Number
NCT01311622
Locations
🇬🇧

Research Site, London, United Kingdom

BAY73-4506 Probe Substrate Study

First Posted Date
2011-02-01
Last Posted Date
2019-07-10
Lead Sponsor
Bayer
Target Recruit Count
41
Registration Number
NCT01287598
Locations
🇨🇦

Cross Cancer Institute, Edmonton, Alberta, Canada

🇨🇦

Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada

🇨🇦

British Columbia Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada

and more 1 locations

A Study of LY2216684 and Warfarin in Healthy Subjects

Phase 1
Completed
Conditions
Interventions
First Posted Date
2010-12-20
Last Posted Date
2019-01-22
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
18
Registration Number
NCT01263119
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States

Human Cytochrome P450 4F Enzymes and Drug Interactions

First Posted Date
2010-11-30
Last Posted Date
2013-01-21
Lead Sponsor
University of North Carolina, Chapel Hill
Target Recruit Count
19
Registration Number
NCT01250535
Locations
🇺🇸

University of North Carolina, Clinical and Translational Research Center (CTRC), Chapel Hill, North Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath